Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | Milan | Healthcare | Pharmaceuticals | €610.33B | 64x | 0.77 | €676.50 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson | Milan | Healthcare | Pharmaceuticals | €341.13B | 18.1x | -0.41 | €140.60 | 5.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbvie | Milan | Healthcare | Pharmaceuticals | €289.78B | 81.4x | -2.6 | €162.80 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Milan | Healthcare | Pharmaceuticals | €138.34B | 27x | 0.47 | €253.35 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Milan | Healthcare | Pharmaceuticals | €119.87B | 17.8x | 0.01 | €21.20 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Milan | Healthcare | Pharmaceuticals | €117.60B | 23x | 0.02 | €94.39 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vertex Pharmaceuticals | Milan | Healthcare | Pharmaceuticals | €103.75B | -122.6x | 0.96 | €400.35 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Milan | Healthcare | Pharmaceuticals | €101.36B | 16.7x | 0.41 | €83.20 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb | Milan | Healthcare | Pharmaceuticals | €81.32B | 17.7x | 0.09 | €40.21 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zoetis | Milan | Healthcare | Pharmaceuticals | €58.03B | 27.2x | 3.69 | €129.68 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Regeneron Pharmaceuticals | Milan | Healthcare | Pharmaceuticals | €49.84B | 13.2x | 0.78 | €474.10 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Milan | Healthcare | Pharmaceuticals | €48.02B | 17x | 4.89 | €111.15 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Milan | Healthcare | Pharmaceuticals | €48.02B | 11.9x | 0.02 | €70.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer | Milan | Healthcare | Pharmaceuticals | €27.08B | -8.3x | 1.8 | €27.20 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen | Milan | Healthcare | Pharmaceuticals | €16.20B | 12.7x | 0.48 | €109.25 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Incyte | Milan | Healthcare | Pharmaceuticals | €11.52B | 648.2x | -6.39 | €58.82 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Recordati | Milan | Healthcare | Pharmaceuticals | €10.73B | 25.7x | 3.42 | €52 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.2% Upside | Upgrade to Pro+ | |
Moderna | Milan | Healthcare | Pharmaceuticals | €10.67B | -3.7x | -0.08 | €27 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomarin Pharmaceutical | Milan | Healthcare | Pharmaceuticals | €9.63B | 21.2x | 0.14 | €49.62 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion Oyj | Milan | Healthcare | Pharmaceuticals | €9.31B | 26.6x | 0.44 | €66.30 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viatris | Milan | Healthcare | Pharmaceuticals | €9.17B | -2.8x | 0 | €7.64 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Swedish Orphan Biovitrum AB | Milan | Healthcare | Pharmaceuticals | €8.59B | 24.3x | 0.32 | €25.66 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols | Milan | Healthcare | Pharmaceuticals | €7.36B | 42.2x | €11.67 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Organon | Milan | Healthcare | Pharmaceuticals | €2.15B | 3.3x | -0.11 | €8.29 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pharmanutra | Milan | Healthcare | Pharmaceuticals | €443.19M | 26.8x | 0.88 | €46.15 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Laboratorio Farmaceutico Erfo | Milan | Healthcare | Pharmaceuticals | €10.81M | 25.2x | -0.76 | €1.26 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |